![\"\"](\"https:\/\/dailybusinessgroup.co.uk\/wp-content\/uploads\/2026\/03\/Bioliberty-Co-founder-and-Chief-Executive-Officer-Rowan-Armstrong-wearing-Biolibertys-Lifeglov-.png\")
University healthtech spin-out Bioliberty has received a further \u00a36.2 million from investors to underpin its rehabilitation technology in Scotland and expansion in the US.<\/p>\n
The company\u2019s platform combines AI with soft?robotic wearable devices to help those recovering from mobility-limiting conditions or injuries.<\/p>\n
It emerged from the University of Edinburgh and is headquartered at The National Robotarium on the Heriot-Watt campus<\/p>\n
The Series A round was led by the Scottish National Investment Bank (SNIB), alongside existing investors Archangels, Eos Advisory, Old College Capital, and Hanna Capital SEZC, as well as new investor Conduit Connect. It takes investment since last summer to \u00a37.7m.<\/p>\n
Rowan Armstrong, co?founder and chief executive officer of Bioliberty, said: \u201cScotland has provided a strong foundation for Bioliberty, offering access to world?class engineering talent and a highly collaborative research environment.<\/p>\n
\u201cThis funding will enable us to grow our team in Scotland, create high?value jobs, and continue building technology here that supports better rehabilitation outcomes.\u201d<\/p>\n
Ailsa Young, investment director at SNIB, said: \u201cBioliberty\u2019s founders are ambitious, talented, and have developed an impressive solution to meet the needs of patients against the backdrop of rising healthcare costs and a strain on delivery.\u201d<\/p>\n
Shaolei McKie, senior investment manager at Archangels, said: \u201cArchangels has supported Bioliberty, alongside our syndicate partners, since early 2023 through its initial product development and early commercialisation.<\/p>\n
\u201cThe founding team has developed technology with genuine clinical value and real potential to scale into global markets.\u201d<\/p>\n
\t <\/div>\n